Member Info for Elartu

Cutting edge AI techniques bring new hope for Alzheimer’s patients
AI tool analyses the MRI brain scans of thousands of living Alzheimer’s patients

https://inews.co.uk/news/health/cutting-edge-ai-techniques-bring-new-hope-for-alzheimers-patients/

Article doesn't actually mention TexRAD but it's a distinct possibility.

1. "The new tool analyses brain scans with an algorithm that has been developed by using new machine learning techniques to process thousands of other MRI scans of living Alzheimer’s patients." - definite TexRAD territory.

2. "Professor Daniel Alexander, of University College London." - good connections to TexRAD - Balaji Ganeshan is a UCL Senior Research Analyst and UCL is a reference site for TexRAD.

3. "The study also involved more than 10 other institutions, including the University of Cambridge, the Erasmus Medical Center in Rotterdam, the Universities of Brescia and Milan in Italy, the University of Toronto and the Karolinska Institutet in Stockholm." -
a. University of Cambridge - research user.
b. Erasmus Medical Centre - no known connection.
c. University of Brescia - research user.
d. University of Milan - research user.
e. University of Toronto - research user.
f. Karolinska Institutet Stockholm - no known connection other than Chris Chatwin.

"This company will, I believe, climb significantly in value" - Alan Green talks stutteringly about potential "sleeping giant" FDBK on Vox Markets Podcast starting at 30:12.

https://audioboom.com/posts/7049194-john-meyer-on-cora-bmn-arcm-and-alan-green-on-pdz-gkp-fdbk-vast

The nether regions are where the interesting snippets reside. Siemens 'bundling', US Patents, Nvidia & Future Processing, dating site information. Who knows what will appear next? Ferrets rule.

12p by start of 2019 Bob?

Mostly down to an MM having a negative number of shares in their ledger and now getting punished for it.

Red in the ledger.

https://www.youtube.com/watch?v=B9uRUW4BM8M

...on every little buy this morning.

https://www.youtube.com/watch?v=s7UsEjVy1qY

Hi Shaz,

Current on line limits for me are :
Sell 625k @ 1.52p (rising to 1.6138p for smaller amounts).
Buy 15k @ 1.694p.

https://twitter.com/FBKmed/status/1052149977135415296

https://www.turing-gateway.cam.ac.uk/event/tgmw61

The jargon is a problem for us non-medics but seeing the patents being applied for is much easier. Partners are pushing forward with these nowadays. I can see a time in the near future when we have products in the marketplace for not just TexRAD Lung, but also TexRAD Liver, Gastric and Breast. More are turning up all the time and as long as we keep searching we will find them.

A couple of weeks ago (Oct 2nd) I posted the following regarding a patent from Imaging Endpoints for Diagnosing Breast Cancer using TexRAD as the Quantitative Textural Analysis medium.

https://patentimages.storage.googleapis.com/0e/aa/fc/0ab1970f8f10ae/US20180268107A1.pdf

Today I found another patent from Imaging Endpoints for Predicting Breast Cancer Responsiveness to Hormone Treatment using Quantitative Textural Analysis again using TexRAD.

https://patentimages.storage.googleapis.com/a8/f2/8d/7283c4bf123de5/US20180285531A1.pdf

It looks as though TexRAD is moving into breast cancer diagnosis and predictive responsiveness in a big way.

A couple of weeks ago (Oct 2nd) I posted the following regarding a patent from Imaging Endpoints for Diagnosing Breast Cancer using TexRAD as the Quantitative Textural Analysis medium.

Https://patentimages.storage.googleapis.com/0e/aa/fc/0ab1970f8f10ae/US20180268107A1.pdf

Today I found another patent from Imaging Endpoints for Predicting Breast Cancer Responsiveness to Hormone Treatment using Quantitative Textural Analysis again using TexRAD.

Https://patentimages.storage.googleapis.com/a8/f2/8d/7283c4bf123de5/US20180285531A1.pdf

It looks as though TexRAD is moving into breast cancer diagnosis and predictive responsiveness in a big way.

Is that you Bo? Horsford? Bob?

I'm here Horsford. Convinced the MM's are short on shares by a few million and they are now adjusting to the fact that they are not likely to pick up what they need by lowering the price. A new realism is beginning to take place.

Congratulations Bo. You have officially won the contest to find the longest link ever.

The American Journal of Neuroradiology - On page 121 (1878) of the 212 page document. Throat Cancer study using TexRAD.

Correlation between Human Papillomavirus Status and Quantitative MR Imaging Parameters including Diffusion-Weighted Imaging and Texture Features in Oropharyngeal Carcinoma

http://www.ajnr.org/content/39/10.complete-issue.pdf

Texture analysis was performed on primary tumors. MR images were transferred to an off-line PC and analyzed using proprietary texture analysis software TexRAD (TexRAD; Cambridge, UK). Three head and neck radiologists in consensus (M.R., M.L., E.T.), blinded to HPV status, drew an ROI on a single section of axial T2, ADC map, and post contrast VIBE images (Fig 1), encompassing the primary tumor on its largest axial area. TexRAD software uses
the filtration-histogram method as described by Miles et al.26 The filtration-histogram method comprises an initial filtration step that highlights image features of a specified size, followed by histogram analysis of the filtered image. The size of highlighted image features is denoted by the spatial scaling factor (SSF), expressed in millimeters.

To grow faster...

Current on line limits are -
Buy 1k at 1.6p (yes, really, 1,000 only).
Sell 500K at 1.4077p.

Paul, you are a rare investor if you'd rather a company wasn't open and aboveboard. Plenty of deceitful companies around if you prefer that class.

"The Company is considering additional funding for its mid-term working capital requirements and to deliver on its longer-term growth opportunities and plans to raise the additional capital through public or private financings and/or partnering opportunities."
________________________________________________

Note the reference to "mid-term working capital requirements".

It is generally accepted that 'near-term' funding refers to the current financial year, 'mid-term' funding is for 1 to 3 years after the current financial year, and 'long term' funding is for 3 years and beyond the current financial year.

The funding the company seeks may still be a good few months away as it is classified as 'mid-term' funding. Financial year end for Feedback is end of May so perhaps expect it around that time.

Please refrain from speculation postings Paul or you will look as daft as 'neonred' did yesterday afternoon.

It's mentioned here Cash.

https://www.ekfdiagnostics.com/successful-fundraising-and-proposed-aim-admission-of-renalytix-ai-plc.html

Looks like a very large portion of the company is still going to be controlled by EKF shareholders.

You couldn't be more wrong if you tried.

More buys than sells today and the MM's are oh so short of stock which is why the on line quote shows:

Current on line limits are -
Buy 20k at 1.494p
Sell 1 million at 1.33p.